Inorganic arsenite potentiates vasoconstriction through calcium sensitization in vascular smooth muscle

Environmental Health Perspectives

Volumn 113, Issue 10, 2005, Pages 1330-1335

  Lee, Moo Yeol ^a   Lee, Young Ho ^b   Lim, Kyung Min ^a   Chung, Seung Min ^a   Bae, Ok Nam ^a   Kim, Heon ^c   Lee, Choong Ryeol ^d   Park, Jung Duck ^e   Chung, Jin Ho ^a  

^a Seoul National University   (South Korea)

^b Yonsei University   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

^d Ulsan University College of Medicine   (South Korea)

^e Chung Ang University   (South Korea)

Author keywords

Arsenic; Arsenite; Blood vessels; Calcium sensitization; Cardiovascular disease; Myosin light chain phosphorylation; Vasoconstriction

Indexed keywords

ARSENIC; ARSENIC ACID; ARSENIC TRIOXIDE; CACODYLIC ACID; CALCIUM; FURA 2; METHANEARSONIC ACID; MYOSIN LIGHT CHAIN; PHENYLEPHRINE; POTASSIUM ION; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SENSITIZATION; SMOOTH MUSCLE CONTRACTION; VASCULAR DISEASE; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; ARSENITES; BLOOD PRESSURE; CALCIUM; MALE; MUSCLE, SMOOTH, VASCULAR; MYOSIN LIGHT CHAINS; PHENYLEPHRINE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION;

ANIMALIA;

EID: 27244452270     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.8000     Document Type: Article

References (41)

1. Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, et al. 1999. Arsenic health effects, mechanisms of actions, and research issues. Environ Health Perspect 107:593-597.
2. Bohr DF, Dominiczak AF, Webb RC. 1991. Pathophysiology of the vasculature in hypertension. Hypertension 18(5 suppl):III69-75.
3. Bruckner R, Meyer W, Mugge A, Schmitz W, Scholz H. 1984. Alpha-adrenoceptor-mediated positive inotropic effect of phenylephrine in isolated human ventricular myocardium. Eur J Pharmacol 99:345-347.
4. Carmignani M, Boscolo P, Castellino N. 1985. Metabolic fate and cardiovascular effects of arsenic in rats and rabbits chronically exposed to trivalent and pentavalent arsenic. Arch Toxicol Suppl 8:452-455.
5. Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. 1996. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol 16:504-510.
6. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, et al. 1995. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53-60.
7. Chen WY, Yen TS. 1964. Experimental studies on the drinking water of blackfoot endemic area. 2. Studies on the effects of drinking water of blackfoot endemic area on peripheral vascular perfusion of the hind limbs of frogs. Tsa Chih Gaoxiong Yi Xue Yuan Tong Xue Hui 63:150-158.
8. Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. 1997. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28:1717-1723.
9. ++ mobilization induced by alpha-1 adrenoceptor stimulation in the rat aorta. J Pharmacol Exp Ther 240:123-127.
10. Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. 1994. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev 16:184-209.
11. Fukata Y, Amano M, Kaibuchi K. 2001. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 22:32-39.
12. Horowitz A, Menice CB, Laporte R, Morgan KG. 1996. Mechanisms of smooth muscle contraction. Physiol Rev 76:967-1003.
13. Huang RN, Lee TC. 1996. Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol Appl Pharmacol 136:243-249.
14. Lee MY, Bae ON, Chung SM, Kang KT, Lee JY, Chung JH. 2002. Enhancement of platelet aggregation and thrombus formation by arsenic in drinking water: a contributing factor to cardiovascular disease. Toxicol Appl Pharmacol 179:83-88.
15. Lee MY, Jung BI, Chung SM, Bae ON, Lee JY, Park JD, et al. 2003. Arsenic-induced dysfunction in relaxation of blood vessels. Environ Health Perspect 111:513-517.
16. Mohri M, Koyanagi M, Egashira K, Tagawa H, Ichiki T, Shimokawa H, et al. 1998. Angina pectoris caused by coronary microvascular spasm. Lancet 351:1165-1169.
17. Moncada S, Rees DD, Schulz R, Palmer RM. 1991. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 88:2166-2170.
18. Mulvany MJ, Aalkjaer C. 1990. Structure and function of small arteries. Physiol Rev 70:921-961.
19. Nordstrom DK 2002. Public health. Worldwide occurrences of arsenic in ground water. Science 296:2143-2145.
20. Oremland RS, Stolz JF. 2003. The ecology of arsenic. Science 300:939-944.
21. 2+, and tension in intact smooth muscles. Am J Physiol 260:C917-C925.
22. Peroutka SJ. 1984. Vascular serotonin receptors. Correlation with 5-HT1 and 5-HT2 binding sites. Biochem Pharmacol 33:2349-2353.
23. Pi J, Horiguchi S, Sun Y, Nikaido M, Shimojo N, Hayashi T, et al. 2003. A potential mechanism for the impairment of nitric oxide formation caused by prolonged oral exposure to arsenate in rabbits. Free Radic Biol Med 35:102-113.
24. Rahman M, Tondel M, Ahmad SA, Chowdhury IA, Faruquee MH, Axelson O. 1999. Hypertension and arsenic exposure in Bangladesh. Hypertension 33:74-78.
25. Rossman TG. 2003. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 533:37-65.
26. Rubanyi GM. 1993. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 22(suppl 4):S1-S14.
27. Sakurada K, Seto M, Sasaki Y. 1998. Dynamics of myosin light chain phosphorylation at Ser19 and Thr18/Ser19 in smooth muscle cells in culture. Am J Physiol 274:C1563-C1572.
28. Sanders KM. 2001. Invited review: mechanisms of calcium handling in smooth muscles. J Appl Physiol 91:1438-1449.
29. Schoen A, Beck B, Sharma R, Dube E. 2004. Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol Appl Pharmacol 198:253-267.
30. Simeonova PP, Hulderman T, Harki D, Luster MI. 2003. Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ Health Perspect 111:1744-1748.
31. Smith AH, Lopipero PA, Bates MN, Steinmaus CM. 2002. Public health. Arsenic epidemiology and drinking water standards. Science 296:2145-2146.
32. Somlyo AP, Somlyo AV. 1994. Signal transduction and regulation in smooth muscle. Nature 372:231-236.
33. Somlyo AP, Somlyo AV. 2000. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 522 Pt 2:177-185.
34. Tseng CH. 2004. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol 197:6743.
35. Tseng CH, Chong CK, Chen CJ, Lin BJ, Tai TY. 1995. Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot-disease-hyperendemic villages in Taiwan. Int J Microcirc Clin Exp 15:21-27.
36. Tseng WP. 1977. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 19:109-119.
37. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. 1997. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990-994.
38. Vanhoutte PM. 1997. Endothelial dysfunction and atherosclerosis. Eur Heart J 18(suppl E):E19-E29.
39. Walsh MP. 1994. Regulation of vascular smooth muscle tone. Can J Physiol Pharmacol 72:919-936.
40. Wang CH, Jeng JS, Yip PK, Chen CL, Hsu LI, Hsueh YM, et al. 2002. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 105:1804-1809.
41. Yu HS, Sheu HM, Ko SS, Chiang LC, Chien CH, Lin SM, et al. 1984. Studies on blackfoot disease and chronic arsenism in southern Taiwan: with special reference to skin lesions and fluorescent substances. J Dermatol 11:361-370.